TG Therapeutics (NASDAQ: TGTX) reported Q2 EPS of ($0.30), $0.21 better than the analyst estimate of ($0.51). Revenue for the quarter came in at $594 thousand versus the consensus estimate of $175.43 thousand.

For earnings history and earnings-related data on TG Therapeutics (TGTX) click here.